CSPC Pharmaceutical Group (01093.HK): New Drug Application for Valsartan Levoamlodipine Maleate Tablets Accepted

NewTimeSpace News: On June 16, 2026, CSPC Pharmaceutical Group (01093.HK) announced that the marketing application for Valsartan Levoamlodipine Maleate Tablets (specification: 80mg/2.5mg) has been accepted by the National Medical Products Administration.

As disclosed in the announcement, Levoamlodipine Maleate (Xuanining®) is the first original Chinese antihypertensive drug fully approved by the U.S. FDA. Phase III clinical studies demonstrate that this combination product delivers markedly superior antihypertensive efficacy versus monotherapy. It takes therapeutic effect in 4 weeks and achieves stable blood pressure control after 8 weeks, with no additional safety risks and a low incidence of adverse reactions such as peripheral edema.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.